Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2011. The report details a specific share repurchase transaction executed on June 13, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 735,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,288.5 pence per share; lowest price paid was 1,272 pence per share.
- Treasury Shares: Following cancellation, the Company holds 499,174,284 shares in Treasury.
- Treasury Ownership: Represents 8.83% of total issued share capital and 9.69% of total voting rights.
- Shares in Issue: 5,151,149,277 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's issued share capital through the cancellation of 735,000 repurchased shares. This action increased the proportion of Treasury shares held by the Company to 8.83% of total issued share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,151,149,277) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (499,174,284) and its impact on voting rights (9.69%).
- Review the Annual General Meeting minutes from May 5, 2011, to confirm the scope of the share repurchase authority utilized.